GR1000597B - Παραγοντας αναστολης αναπτυξης και χρηση του. - Google Patents
Παραγοντας αναστολης αναπτυξης και χρηση του.Info
- Publication number
- GR1000597B GR1000597B GR890100029A GR890100029A GR1000597B GR 1000597 B GR1000597 B GR 1000597B GR 890100029 A GR890100029 A GR 890100029A GR 890100029 A GR890100029 A GR 890100029A GR 1000597 B GR1000597 B GR 1000597B
- Authority
- GR
- Greece
- Prior art keywords
- growth inhibitor
- tissue
- suspension agent
- organic
- compound
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factors [FGF]
- C07K14/503—Fibroblast growth factors [FGF] basic FGF [bFGF]
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/21—Acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/22—Lipids, fatty acids, e.g. prostaglandins, oils, fats, waxes
- A61L2300/222—Steroids, e.g. corticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
- A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
Abstract
Παθολογικά ή διαφορετικά ανεπιθύμητες αναπτύξεις ιστού ή κυττάρων σε θηλαστικά, περιλαμβανομένων ανθρώπων, αναστέλλονται με την χορήγηση σε αυτά μιας σύνθεσης που δίνεται ως παράδειγμα από (1) ένα ευδιάλυτο σε νερό θειϊκό αλάτι κυκλοδεξτρίνης, μαζί με (2) μια οργανική ένωση αναστολής ανάπτυξης. Η ένωση αναστολής ανάπτυξης (2) μπορεί να είναι ένα στεροειδές έχοντας μη ανασταλτική αποτελεσματικότητα με απουσία του (1), ή μια οργανική ένωση που μπορεί να είναι ένας ενεργός αναστολέας ανάπτυξης, η δράση της οποίας δυναμικοποιείται από (1). Η εφεύρεση παρέχει μια μέθοδο ανστολής αγγειογένεσης και ελέγχου της ανάπτυξης νεοπλασμάτων καθώς και θεραπείας άλλων διαταραχών και παθολογικών καταστάσεων που συνδυάζονται με ανεπιθύμητη ανάπυξη ιστών και κυττάρων, περιλαμβανομένης της αγγειογένεσης. ω
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14540788A | 1988-01-19 | 1988-01-19 | |
US29563889A | 1989-01-10 | 1989-01-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
GR1000597B true GR1000597B (el) | 1992-08-26 |
Family
ID=26842946
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GR890100029A GR1000597B (el) | 1988-01-19 | 1989-01-17 | Παραγοντας αναστολης αναπτυξης και χρηση του. |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0398925B1 (el) |
JP (1) | JP2995069B2 (el) |
KR (1) | KR900700114A (el) |
CN (1) | CN1038304C (el) |
DE (1) | DE68910113T2 (el) |
DK (1) | DK171390A (el) |
ES (1) | ES2017808A6 (el) |
GR (1) | GR1000597B (el) |
IE (1) | IE64346B1 (el) |
IL (1) | IL88970A (el) |
WO (1) | WO1989006536A1 (el) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5760015A (en) * | 1988-01-19 | 1998-06-02 | The Trustees Of The University Of Pennsylvania | Cyclodextrin compounds and methods of making and use thereof |
US5637575A (en) * | 1988-01-19 | 1997-06-10 | The Trustees Of The University Of Pennsylvania | Methods of inhibiting restenosis |
US5183809A (en) * | 1990-02-15 | 1993-02-02 | The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation | Cyclodextrin polymers and cyclodextrins immobilized on a solid surface |
US5658894A (en) * | 1989-04-23 | 1997-08-19 | The Trustees Of The University Of Pennsylvania | Compositions for inhibiting restenosis |
JPH02240020A (ja) * | 1989-01-26 | 1990-09-25 | Childrens Medical Center Corp:The | 外科的切除後の腫瘍再発阻止剤 |
US5173481A (en) * | 1989-04-03 | 1992-12-22 | The United States Of America As Represented By The Department Of Health And Human Services | Preparation of specifically substituted cyclodextrins |
US5441944A (en) * | 1989-04-23 | 1995-08-15 | The Trustees Of The University Of Pennsylvania | Substituted cyclodextrin sulfates and their uses as growth modulating agents |
WO1991013100A1 (en) * | 1990-03-02 | 1991-09-05 | Australian Commercial Research & Development Limited | Cyclodextrin compositions and methods for pharmaceutical and industrial applications |
US5227372A (en) * | 1990-03-07 | 1993-07-13 | Children's Medical Center Corporation | Method for retaining ophthalmological agents in ocular tissues |
TW282399B (el) * | 1990-05-25 | 1996-08-01 | Takeda Pharm Industry Co Ltd | |
US5446030A (en) * | 1991-09-19 | 1995-08-29 | Weisz; Paul B. | Prevention of hemolysis |
JPH08511041A (ja) * | 1993-03-31 | 1996-11-19 | ザ トラスティーズ オブ ザ ユニバーシティー オブ ペンシルバニア | 哺乳動物生組織の増殖に作用する方法、及びそのための化合物ならびに組成物 |
ATE154757T1 (de) * | 1993-07-19 | 1997-07-15 | Angiotech Pharm Inc | Anti-angiogene mittel und verfahren zu deren verwendung |
US5753230A (en) | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
US7053041B1 (en) | 1996-05-31 | 2006-05-30 | The Scripps Research Institute | Methods and compositions useful for inhibition of αvβ5mediated angiogenesis |
RU2195312C2 (ru) | 1996-05-31 | 2002-12-27 | Дзе Скриппс Рисерч Инститьют | СПОСОБЫ И КОМПОЗИЦИИ, ИСПОЛЬЗУЕМЫЕ ДЛЯ ИНГИБИРОВАНИЯ αvβ5-ОПОСРЕДОВАННОГО АНГИОГЕНЕЗА |
GB9625193D0 (en) * | 1996-12-04 | 1997-01-22 | Ml Lab Plc | Treatment of highly vascular tumours |
AU2006249816A1 (en) * | 2005-05-25 | 2006-11-30 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
WO2009075565A1 (en) * | 2007-12-12 | 2009-06-18 | Erasmus University Medical Center Rotterdam | Methods for controlling vasculogenesis |
CA2738018A1 (en) | 2008-09-22 | 2010-03-25 | Arcarios B.V. | Carboxyethylated cyclodextrin polysulfates useful as medicaments |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5036422A (el) * | 1973-08-07 | 1975-04-05 | ||
US4247535A (en) * | 1979-11-05 | 1981-01-27 | American Cyanamid Company | Modified cyclodextrin sulfate salts as complement inhibitors |
US4258180A (en) * | 1979-11-05 | 1981-03-24 | American Cyanamid Company | C6-Modified cyclodextrin sulfate salts as complement inhibitors |
FR2484252A1 (fr) * | 1980-05-09 | 1981-12-18 | Chinoin Gyogyszer Es Vegyeszet | Procede de preparation de solutions aqueuses de composes organiques biologiquement actifs insolubles ou peu solubles dans l'eau |
WO1985002767A1 (en) * | 1983-12-21 | 1985-07-04 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
EP0197571A2 (en) * | 1985-03-15 | 1986-10-15 | Janssen Pharmaceutica N.V. | Novel derivatives of gamma-cyclodextrin |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4020160A (en) * | 1975-08-15 | 1977-04-26 | American Cyanamid Company | Cyclodextrin sulfate salts as complement inhibitors |
US4066829A (en) * | 1976-07-12 | 1978-01-03 | American Cyanamid Company | Malto-dextrin poly(H-)sulfates |
JPS53109953A (en) * | 1977-11-21 | 1978-09-26 | Osamu Asano | Pharmaceutical composition having solid tumor controlling action |
US4383992A (en) * | 1982-02-08 | 1983-05-17 | Lipari John M | Water-soluble steroid compounds |
US4757056A (en) * | 1984-03-05 | 1988-07-12 | Hepar Industries, Inc. | Method for tumor regression in rats, mice and hamsters using hexuronyl hexosaminoglycan-containing compositions |
US4596795A (en) * | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
US4727064A (en) * | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
JPS61165322A (ja) * | 1985-01-14 | 1986-07-26 | Microbial Chem Res Found | スパガリン類の注射用凍結乾燥製剤 |
US4783446A (en) * | 1985-11-22 | 1988-11-08 | Neushul Mariculture Incorporated | Method for the treatment of AIDS virus and other retroviruses |
ATE160872T1 (de) * | 1990-01-31 | 1997-12-15 | Ladislav Novotny | Verfahren zur herstellung eines kapillaren glasröhrchens für miniaturisierte sensoren |
-
1989
- 1989-01-17 EP EP89901794A patent/EP0398925B1/en not_active Expired - Lifetime
- 1989-01-17 GR GR890100029A patent/GR1000597B/el unknown
- 1989-01-17 JP JP1501676A patent/JP2995069B2/ja not_active Expired - Lifetime
- 1989-01-17 WO PCT/US1989/000175 patent/WO1989006536A1/en active IP Right Grant
- 1989-01-17 IE IE12589A patent/IE64346B1/en not_active IP Right Cessation
- 1989-01-17 DE DE89901794T patent/DE68910113T2/de not_active Expired - Fee Related
- 1989-01-17 KR KR1019890701714A patent/KR900700114A/ko not_active Application Discontinuation
- 1989-01-17 CN CN89101050A patent/CN1038304C/zh not_active Expired - Fee Related
- 1989-01-17 IL IL88970A patent/IL88970A/xx not_active IP Right Cessation
- 1989-01-17 ES ES8900157A patent/ES2017808A6/es not_active Expired - Lifetime
-
1990
- 1990-07-17 DK DK171390A patent/DK171390A/da not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5036422A (el) * | 1973-08-07 | 1975-04-05 | ||
US4247535A (en) * | 1979-11-05 | 1981-01-27 | American Cyanamid Company | Modified cyclodextrin sulfate salts as complement inhibitors |
US4258180A (en) * | 1979-11-05 | 1981-03-24 | American Cyanamid Company | C6-Modified cyclodextrin sulfate salts as complement inhibitors |
FR2484252A1 (fr) * | 1980-05-09 | 1981-12-18 | Chinoin Gyogyszer Es Vegyeszet | Procede de preparation de solutions aqueuses de composes organiques biologiquement actifs insolubles ou peu solubles dans l'eau |
WO1985002767A1 (en) * | 1983-12-21 | 1985-07-04 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
EP0197571A2 (en) * | 1985-03-15 | 1986-10-15 | Janssen Pharmaceutica N.V. | Novel derivatives of gamma-cyclodextrin |
Non-Patent Citations (10)
Title |
---|
CHEMICAL ABSTRACTS, vol. 83, no. 9, 1st September 1975, abstract no. 79544a, Columbus, Ohio, US; & JP-A-75 36 422 (AJINOMOTO CO., INC.) 05-04-1975 * |
CLAIMS NOT SEARCHED: 10-19 * |
CLAIMS SEARCHED COMPLETELY: 1-9 * |
DIALOG INFORMATION SERVICES, FILE 155 (MEDLINE), accession no. 06630385; D. INGBER et al.: "Inhibition of angiogenesis through modulation of collagen metabolism", & LAB. INVEST., vol. 59, no. 1, July 1988, pp. 44-51 (Cat. D) * |
J. CELL. BIOL., vol. 107, no. 6, part 3, December 1988, page 579A, abstract no. 3277; J. FOLKMAN et al.: "A synthetic heparin-mimic modulates angiogenesis and provides a mechanistic model for potentiation of angiostatic steroids" * |
J. NATL. CANCER INST., vol. 75, no. 2, August 1985, pages 353-359; W.D. KLOHS et al.: "Collagen-production inhibitors evaluated as antitumor agents" * |
JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 72, no. 10, October 1983, pages 1215-1217, American Pharmaceutical Association; S.G. FRANK et al.: "Investigation of the beta-cyclodextrin-hydrocortisone inclusion compound" * |
JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 74, no. 9, September 1985, pages 987-990, American Pharmaceutical Association; J. PITHA et al.: "Amorphous water-soluble derivatives of cyclodextrins: nontoxic dissolution enhancing excipients" * |
SCIENCE, vol. 230, no. 4732, 1985, pages 1375-1378; R. CRUM et al.: "A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment" * |
SCIENCE, vol. 243, no. 4897, 17th March 1989, pages 1490-1493; J. FOLKMAN et al.: "Control of angiogenesis with synthetic heparin substitutes" * |
Also Published As
Publication number | Publication date |
---|---|
DE68910113T2 (de) | 1994-03-17 |
JPH03502323A (ja) | 1991-05-30 |
EP0398925A1 (en) | 1990-11-28 |
EP0398925A4 (en) | 1991-07-03 |
ES2017808A6 (es) | 1991-03-01 |
DK171390A (da) | 1990-08-21 |
KR900700114A (ko) | 1990-08-11 |
WO1989006536A1 (en) | 1989-07-27 |
CN1036135A (zh) | 1989-10-11 |
CN1038304C (zh) | 1998-05-13 |
IE64346B1 (en) | 1995-07-26 |
DK171390D0 (da) | 1990-07-17 |
EP0398925B1 (en) | 1993-10-20 |
JP2995069B2 (ja) | 1999-12-27 |
IE890125L (en) | 1989-07-19 |
IL88970A (en) | 1993-05-13 |
DE68910113D1 (de) | 1993-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GR1000597B (el) | Παραγοντας αναστολης αναπτυξης και χρηση του. | |
ATE242632T1 (de) | Verwendung von betulinsäure-derivaten zur behandlung und vorbeugung von melanomen | |
EA200000723A1 (ru) | Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола | |
DE69311361T2 (de) | Zusammensetzungen zur behandlung von glaukoma die prostaglandine und clonidinderivate enthalten | |
ATE288749T1 (de) | Verwendung von kannabidiol als entzündunghemmende mittel | |
RU94031102A (ru) | Сульфамиды в качестве антагонистов эндотелина и способ лечения соответствующих заболеваний | |
MX9306960A (es) | Composiciones de extracto de corteza de roble, compositiones sinteticasrelacionadas, y metodo para su utilizacion. | |
MX9203811A (es) | Esteroides para uso como inmunomoduladores. | |
NO985232D0 (no) | Androstenderivater | |
DE60013266D1 (de) | Steroidnitrate zur behandlung von oxidativen schädigungen und endothelialer dysfunktion | |
DE69430816D1 (de) | Verwendung von Piperidin-Derivaten in der Behandlung von Schizophrenie | |
BR9808221A (pt) | Método de tratamento de tumor. | |
ATE271873T1 (de) | Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz | |
BR9912024A (pt) | Emplastros em gel contento esteróide e processo para a produção dos mesmos | |
ES2158938T3 (es) | Derivados de aminoquinazolina que tienen actividad alfa-antagonistas. | |
ES2071080T3 (es) | Igf-i para tratar el efecto adverso de la terapia con esteroides. | |
EA199700241A1 (ru) | Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран | |
ES2061811T3 (es) | Uso de compuestos de gamma-oxibutenolido conjugados para tratar ulcera. | |
FI895084A0 (fi) | 3b, 17b-hydroxisubstituerade steroider och steroida naerbeslaektade foereningar. | |
ATE206052T1 (de) | Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten | |
ES2154290T3 (es) | Estimulacion de la diferenciacion celular por sindecano. | |
DE69231222D1 (de) | Naphtochinonderivate zur Behandlung von chronischen Entzündungen | |
ES2026485T3 (es) | Esteres de salsalato con guayacol para tratar bronconeumopatias flogisticas. | |
MX9203739A (es) | Complejo organico de oro aplicado topicamente. | |
ES2040750T3 (es) | Un procedimiento para la preparacion de un derivado de isoquinolinol. |